By Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics, Q2 Solutions
At Q2 Solutions, we are helping develop and use biomarkers in oncology trials across the development spectrum. Cancer trials increasingly rely on biomarkers to optimize treatment outcomes for patients. In fact, 60% of the 34 oncology drugs expected to launch in 2017 will be targeted to biomarker-defined patients. The importance of selecting the right biomarker early in the process of development cannot be overstated. Approaches involving the use of biomarkers must fit into the development continuum, starting at the preclinical stage and moving through to diagnostic development.
In this article, learn how we leverage unique genomic technologies and tools to advance our customers' oncology trials. You'll also learn recommendations for avoiding pitfalls and choosing the right patient cohort in cancer studies.